Promising Results for Oncolytic Virotherapy in Treating Recurrent Head and Neck Cancer

Strategic Insights -

Research findings have shed light on the potential of oncolytic virotherapy in treating recurrent head and neck cancer. A recent study published in Virus Research has demonstrated the efficacy and safety of a novel therapeutic approach using VT1093, an oncolytic recombinant herpes simplex virus type 1 engineered to express a PD-1 monoclonal antibody. The open-label, single-arm, dose-escalation Phase I clinical trial conducted in China recruited seven patients with recurrent head and neck cancer, who received either a single or multiple intratumoral injections of VT1093. The results showed a disease control rate (DCR) of 57.1% (4/7) with no treatment-related Grade 3 or higher adverse events. The treatment was generally well tolerated, and no dose-limiting toxicities were observed.

Key Takeaways:

  • The oncolytic virotherapy approach using VT1093 demonstrated promising efficacy in controlling disease progression in recurrent head and neck cancer.
  • Five of the seven patients enrolled in the study achieved stable disease (SD), while one patient had progressive disease (PD), resulting in a DCR of 57.1% (4/7).
  • The most common treatment-related adverse events were mild to moderate fever and fatigue (Grade 1-2), with no Grade 3 or higher events.
  • The treatment was generally well tolerated, with no dose-limiting toxicities observed.
  • VT1093 shows potential as a novel therapeutic approach for recurrent head and neck cancer.
  • This study supports further clinical development of VT1093 for this patient population.
  • Qi Zhong, Siyu Zhu, and other researchers from Capital Medical University and Beijing Tongren Hospital contributed to the study, which has been peer-reviewed.

Statistics:

  • 7 patients with recurrent head and neck cancer were enrolled in the study.
  • 5 patients achieved stable disease (SD).
  • 1 patient had progressive disease (PD).
  • 57.1% (4/7) disease control rate (DCR) was achieved.
  • No Grade 3 or higher treatment-related adverse events were observed.
  • No dose-limiting toxicities were observed.

Sources:

  • Virus Research, 2025:199639.
  • Qi Zhong, Dept. of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University No.1, Dongjiaominxiang Street, Dongcheng District, Beijing 100730, People's Republic of China.
  • Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Virus Research - www.journals.elsevier.com/virus-research/)